Abstract DP030: Impact of Lipoprotein(a) on efficacy and safety of ticagrelor versus clopidogrel in patients with minor stroke or transient ischemic attack: A Post Hoc Analysis of the CHANCE-2 Trial

Background: Lipoprotein (a) is recognized as an independent risk factor for atherosclerotic cardiovascular disease, with its interaction with several platelet receptors offering biological plausibility for a pro-aggregatory effect. Our aim was to evaluate the impact of Lp(a) on the efficacy and safety of ticagrelor–aspirin compared to clopidogrel–aspirin treatment. Methods: This is a post-hoc analysis obtained from Ticagrelor or Clopidogrel with Aspirin in High-Risk Patients with Acute Nondisabling Cerebrovascular Events II (CHANCE-2) trial. The CHANCE-2 trial was a multicentre, randomized, double-blind, placebo-controlled trial, conducted in China, randomized patients with minor stroke or TIA who carried the CYP2C19 loss-of-function allele to receive either ticagrelor– acetylsalicylic acid (ASA) or clopidogrel– ASA. Patients were classified with Lp(a) levels